Decision support training for chronic kidney disease dyads: the ImPart Study protocol Authors: Shena Gazaway, Rachel Wells, Orlando M Gutierrez, Andres Azuero, Alica Cole, Tamara Nix-Parker, Leslie Pitts, Claretha Lyas, Katina Lang-Lindsey, Richard Knight, Patricia Pazant, Neil Gustafuson, Ann Rayburn, Ebele Umeukeje, J Nicholas Odom Published: 2025 ABSTRACT AbstractBackgroundIndividuals living with stage 4 chronic kidney disease and their caregivers face multiple health-related decisions as the disease progresses. The ImPart (Improving the decision-making PARTnership of chronic kidney disease dyads), community-informed, factorial pilot trial intervention aims to train members of the dyad in skills to enhance decision support for patients.MethodsThis single-site pilot 23 factorial trial aims to evaluate the feasibility, acceptability, and preliminary efficacy of the ImPart decision-support training intervention components for individuals with stage 4 chronic kidney disease and their caregivers. Caregivers (n = 64) and patients (n = 64) will be randomly assigned to one of 8 combinations of 3 components with two levels each: (1) caregiver coaching on effective decision support (1 session vs. 3 sessions); (2) caregiver decision support communication training (1 session vs. no session); and (3) patient social support effectiveness psychoeducation (2 sessions vs. no sessions). The primary outcomes of this pilot study are feasibility and acceptability. Secondary outcomes will also be evaluated, including patient decision conflict, quality of life, patient and caregiver distress, and dyadic coping. Results will be used to create a version of ImPart for use in a future fully powered randomized controlled trial.DiscussionThis protocol outlines a pilot factorial trial, guided by the multiphase optimization strategy, to evaluate a community-engaged, co-developed decision-support intervention for individuals with stage 4 chronic kidney disease and their caregivers.Trial registrationNCT 06173323.Keywords: Dyadic decision-making, Factorial trial, Multiphase optimization strategy, Kidney disease Introduction Of the estimated 37 million US adults who live with chronic kidney disease (CKD), nearly 786,000 advance to end-stage disease each year [1]. Individuals with advanced CKD contemplate multiple factors throughout the trajectory of their disease process, manage complex self-management routines, such as medication regimens and nutritional guidelines, and make health-related treatment decisions, such as choosing kidney transplantation, dialysis modality, location of treatment, or conservative treatment [2–4]. Standard nephrology care includes access to CKD educational materials through clinic-based classes or online platforms and the option to seek referrals to dietitians, mental health, and other allied health professionals. Even though these resources are available, our prior qualitative pilot data [5, 6] show that patients and caregivers report being under-informed, unsure about available resources, and desire more information about what is coming next and ways to delay disease progression. CKD patients rely on caregivers when making health-related decisions, including seeking out information, being communicators, helping patients understand the risks and benefits of their options, supporting patients in exploring their values, planning for future decisions, and implementing decisions [7–9]. Literature highlights that when CKD dyads (patient and caregiver) are underprepared to make health-related decisions, both may experience poor coping and heightened distress [9–11]. For patients, as their disease worsens, stress can occur when contemplating health-related decisions. They must process changes to their healthcare plan and self-management strategies, adhere to new medication protocols, and begin considering which renal replacement option is best for them [12]. Caregivers are placed in a stressful supportive role to help the patient cope with these decision-making experiences. Ideally, the dyad would accumulate more information and begin considering care preferences based on personal values [10, 13]. Yet, when dyads are unable to work together effectively, health-related decisions can be made in haste without thoroughly considering the patient’s preferences and desires for treatment as the disease worsens [8, 14–16], resulting in CKD dyads being at high risk of distress when engaging in health-related decision-making [17–19]. Systematic reviews and national reports have highlighted interventions focused on enhancing health-related decision-making early in CKD trajectory. Yet, studies involving caregivers and including robust representation of under-resourced patients are lacking [20–22]. To address the need to optimize the decision partnership between patients and family caregivers, we developed ImPart (IMproving the Decision PARTnership of CKD dyads), a lay coach-led, community-informed, telehealth decision-support intervention to support individuals with CKD and their caregivers when making health-related decisions before illness is severe. Evolving out of our prior decision-support work [23, 24] and following the principles of community-engaged research [25]. We developed the ImPart intervention to address these limitations. First, ImPart is the first decision-support training intervention for CKD dyads designed for early implementation in advancing disease (stage 4) to enhance dyadic partnership and shared decision-making. Second, ImPart was designed with those in the CKD community (patients, caregivers, and clinicians) to ensure the intervention is responsive to the complex needs of CKD dyads. Third, ImPart’s recruitment plan is inclusive of historically under-resourced individuals who experience a high level of disease burden in CKD [26, 27]. Our goal is to create an intervention relevant and appropriate to support decision-making throughout disease progression through the engagement of invested members of the CKD community (patients, clinicians, caregivers, and support organizations). To accomplish this, we need to define which components and component interactions most strongly influence patient and caregiver decision-making outcomes. To address these goals, we are following the Multiphase Optimization Strategy (MOST) framework [28]. We are conducting a pilot optimization factorial trial of the ImPart Intervention and its components to explore feasibility, acceptability, and preliminary efficacy. MOST is a well-validated [29, 30] comprehensive framework for preparing, optimizing, and evaluating multicomponent interventions. The MOST framework, recommended by the Medical Research Council Complex Intervention Guidelines [31], directly responds to the National Academy of Medicine's call for trial designs that disentangle multicomponent interventions [32]. The MOST framework enhances intervention development efficiency by identifying and separating “active” components from “inactive” ones before conducting a randomized controlled trial. Traditional approaches to interventional evaluation can determine neither individual component performance on the outcome of interest nor how components work together (i.e., synergistic or antagonistic interactions). The three intervention components in this ongoing pilot study (caregiver coaching on effective decision support, caregiver decision support communication training, and patient social support effectiveness psychoeducation) are based conceptually on Perlin's Stress Health Model for Family Caregiving [33], Rini’s Social Support Effectiveness theory [34, 35], and the National Institutes of Minority Health and Health Disparities’ theoretical model (Fig. 1) [36]. The study aims to (1) determine feasibility and acceptability of the refined intervention components (feasibility: Predefined ≥ 75% intervention session and data collection completion and feasibility of intervention measure; acceptability: post-intervention acceptability interviews, acceptability of intervention measure, and intervention appropriateness measure) and (2) explore the preliminary efficacy of individual intervention components on patient and caregiver outcomes over 24 weeks. Theoretical foundation Methods Study design This is a single-site, single-blind, 23 factorial pilot trial (2 × 2 ×2 = 8 conditions) of the ImPart dyadic decision support training intervention among 64 caregivers and 64 patients with stage 4 CKD (ClinicalTrails.gov Identifier: NCT06173323). Caregivers are randomly assigned to one of eight experimental conditions (Table 1). Each condition is a unique combination of 3 intervention components, each having two levels. Component levels are (1) caregiver coaching on effective decision support (1 session vs. 3 sessions); (2) caregiver decision support communication training (1 session vs. no session); and (3) patient social support effectiveness psychoeducation (2 sessions vs. no sessions). All enrolled caregiver participants will receive at least one training component; however, only half (n = 32) of patient participants will receive psychoeducation sessions. Table 1ImPart components and components levelsConditionSocial support effectiveness psychoeducation (1 session vs. 3 sessions)Decision support communication training (1 session vs. no session)Patient psychoeducation(2 sessions vs. no sessions)N per condition11 session1 session2 sessionsn = 821 session1 sessionNo sessionn = 831 sessionNo session2 sessionsn = 841 sessionNo sessionNo sessionn = 853 sessions1 session2 sessionsn = 863 sessions1 sessionNo sessionn = 873 sessionsNo session2 sessionsn = 883 sessionsNo sessionNo sessionn = 8 ImPart components and components levels This trial was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board (IRB – 300012221) and is being conducted according to the 1964 Declaration of Helsinki and subsequent amendments. All participants will complete informed consent. Role of the community advisory board Using community-engaged research principles [37], we partnered with an existing community advisory board (CAB) consisting of eight [8] individuals—those with CKD or having received a kidney transplant, those who have cared for someone with CKD, or a CKD-focused clinician. Members of this CAB have collaborated with the study team on two previous studies. The CAB assisted in refining ImPart content based on data from a previously conducted study and their own experiences managing CKD. In addition, the CAB assisted in refining study recruitment procedures and participant materials (i.e., toolkit and recruitment materials). During study start-up and launch, the CAB met monthly. During the data collection phase, the board meets quarterly to receive study updates. In year 4, the CAB will resume monthly meetings to review pilot data based on this protocol to update ImPart components for an R01 clinical trial. All members of the CAB receive a $75 payment for each meeting attended. Setting, eligibility criteria, and recruitment Patient and caregiver participants are being recruited from nephrology clinics associated with UAB (Birmingham, Alabama). Using procedures refined in previous pilot trials [5, 6], team members screen participating nephrology clinicians’ outpatient schedules weekly for potentially eligible patients. Inclusion criteria for patients are as follows: (1) age ≥ 18; (2) medical record documented diagnosis of stage 4 CKD (2 estimated glomerular filtration rate [eGFR] measurements of 15–29 ml/min/1.73m2 at least 90 days apart) [38–40]; (3) ability to speak and read English and complete baseline questionnaires; and (4) having a caregiver willing to participate. Exclusion criteria are as follows: (1) receiving hospice; (2) receiving dialysis; and (3) medical record documentation of active unmedicated severe mental illness, moderate-severe dementia, suicidal ideation, uncorrected hearing loss, and active substance abuse. Inclusion criteria for caregivers are as follows: (1) age ≥ 18; (2) self-endorsing or identified by the patient as “a relative, friend, or partner that has a close relationship with you and who assists you with your medical decisions and who may or may not live in the same residence as you and who is not paid for their help”; (2) caring for a patient with CKD; (3) ability to speak and read English and complete baseline questionnaires; and (4) having a patient who expresses interest in participating and is willing to be enrolled. Exclusion criteria are as follows: (1) self-reported unmedicated mental illness, (2) mild-severe dementia, (3) active suicidal ideation, (4) uncorrected hearing loss, or (5) active substance abuse. After obtaining permission from the nephrology clinician to approach the patient, a study flyer, information sheet, and introduction letter, including opt-out information, are mailed to patients who meet the initial eligibility criteria. The letter provides study details and informs them that a team member will call within the next ten business days. The information sheet describes the study purpose, risks, and how data will be collected and used. During the recruitment call, the study is described further, the information sheet is reviewed, and a secondary screening occurs, which includes asking them if they have a caregiver interested in participating. Eligible and agreeable patients gave informed consent verbally. Caregiver recruitment occurs after the team receives contact information from a consented patient participant. Consented dyads are mailed baseline survey packets. Dyads are randomized by the project manager (PM) after both completed baseline packets (patient and caregiver) are received. See Fig. 2 for overall study flow. Overall study flow. Legend: Social Sup, social support; Com, communication; PPE, patient psychoeducation Randomization and blinding REDCap, a clinical trials management software, is used for study screening, tracking, and data collection. As a dyad, the PM (AC) randomly assigns participants to one of 8 conditions (see Table 1) using a computer-generated algorithm developed by the study statistician (AA) housed in REDCap. Randomization is stratified by race (minority and white) with block lengths of 8, ensuring equal proportions of participants for each condition. After randomization, the project manager notifies the intervention coaches of the dyad’s assigned condition. The principal investigator (PI SG), all co-investigators (JNO, AA, OG), and data collectors (MA, LP) are masked to condition. During phone-based encounters, participants are instructed not to discuss their assignment with the study team. The allocation sequence will remain sealed until the last participant completes 24-week data collection. Conceptual model The ImPart intervention is based on Pearlin’s Stress-Health Model of Family Caregiving [33] and Rini’s Social Support Effectiveness theory [35] (Fig. 1). A and B demonstrate where social and cultural factors intersect around decision-making and serve as a foundation for the illness and caregiving experience based on the National Institute of Minority Health and Health Disparities’ theoretical framework [36]. ImPart is designed to assist the CKD dyad in developing skills to impact decisional partnership by the following: (1) Providing and requesting effective social support (G) through psychoeducation on key principles patients contemplate when making key medical decisions for CKD; (2) Eliciting patient decision needs, including patient values and preferences directly related to kidney replacement therapy choices (H) through better decision support communication (I) and enhancing the quality of decision-making conversations; (3) Providing structured decision support (J) [41, 42] to patients and caregivers that teach one or both to clarify patient values and goals, thereby increasing patients’ decision-making self-efficacy; and (4) Enhancing the CKD patient’s ability to solicit the decision support they need effectively. Modification of these skills and improvement in patient mediating outcomes are hypothesized to decrease patients’ decisional conflict, enhance perceived social/decision support, and improve patient (K) and caregiver wellbeing (L) (decrease distress, increase quality of life) and dyadic coping. The levels in Table 1 are operationalized as differing session frequency (1 session vs. 3 sessions) or on vs. off (2 sessions vs. no sessions). Levels are manipulated in this pilot to explore potential interactions between the factors and gather preliminary data on the acceptability of each factor from the participants’ perspective. The ImPart Intervention and its components Procedures Depending on which condition the dyad is randomized to, caregivers receive between one and four, 20–30-minute telehealth, manualized coaching sessions every 1–2 weeks. The patient receiving manualized coaching sessions is turned on or off (2 sessions vs. no sessions, Table 1). Each caregiver or patient-focused session concludes with an action-planning process led by the decision coach. The action plan focuses on behavioral activation, where participants are prompted to choose a skill or behavior they want to improve based on session content. The plan is reviewed and updated every session. Post randomization, before intervention sessions begin, all caregiver participants and patient participants who receive 2 psychoeducation sessions are mailed an ImPart Toolkit. This toolkit is a 3-ring notebook containing condition-specific content, writing space for self-reflection and notes, and a medical organizer. The medical organizer section includes a calendar, pens/highlights, a case, Post-it notes, and record sheets to track medications, appointments, tests, and medical professional contact information. In addition, copies of home state (Alabama, Georgia, Mississippi) advanced directives forms are provided. Lastly, a resource section includes local and national resources for kidney disease management, self-care, and caregiving support. We will leverage a telehealth mode of intervention delivery, which was found to improve the management of dietary sodium intake and fluid management in CKD patients but has limited support as a method of connection for behavioral intervention delivery [43]. Telehealth delivery is more than just telephone connection due to the sharing of a decision aid—My Transplant Coach© (https://exploretransplant.org/my-transplant-coach/) that is online only. The goal is to direct participants to the website and allow them to view it first with the coach for support. We found in a previous acceptability trial that simply presenting the website over the phone and providing the link was not enough to encourage engagement with the website. To ensure no one is excluded due to known connection barriers (i.e., cost, rural living), we will leverage the Alabama Department of Health telehealth hub infrastructure to facilitate connection with individuals interested in participating but lacking internet connection or comfort. For those requiring this connection option, the study team will work with UAB telemedicine scheduling to arrange an appointment at the health department in their county. Caregiver psychoeducation on effective decision support Half of the caregiver participants will receive a single session focused on providing effective decision support (basic), and the other half will receive three sessions (advanced). For both groups, participants discuss caregiver roles in supporting patients with CKD in their decision-making, attending nephrology appointments, transplantation introduction, dyadic decision-making styles and types, surrogate decision-making, and providing emotional support. In the advanced group, additional discussion topics are the role of values in illness and framing illness decision-making and additional content on advanced care planning and surrogate decision-making. Caregiver decision support communication training Half of the caregiver participants receive a single session on decision support communication training (1 session) and half will not (no session). This content was adapted from caregiving communication skill-building workbooks that have been published and used in our prior works [44, 45]. As an overview, these workbooks review and discuss principles of listening and effective self-expression, including “I” statements. Content was added that reviews tips for communicating effectively with your clinician team and tips for staying engaged during your medical appointment, including bringing prepared questions to ask. Patient psychoeducation on decision partnership Half of the patient participants received two sessions on social support effectiveness and communication (2 sessions); the other half did not (no sessions). The sessions focus on reviewing and discussing the following: (1) how to request effective social support when seeking help with healthcare decisions, (2) educational resources and kidney transplant-specific decision aids, (3) the decision-making partnership with the nephrologist, and (4) introducing concepts related to advanced care planning including durable power of attorney and advanced directives. Monthly follow-up A monthly follow-up call is conducted when coaching sessions are completed for the patients receiving intervention sessions and all caregiver participants. The patients are assigned no sessions and do not receive follow-up calls. During this call, the coach seeks to maintain a human connection with the participant by asking about events and special activities since the last call. The coaches also address any questions or concerns regarding the content of previous calls and goal-setting activities. Acceptability interviews After receiving 24-week surveys from patient and caregiver participants, a study team member will contact them to schedule an acceptability interview. A trained team member will conduct acceptability interviews via telephone, which will be audio-recorded for transcription purposes. Acceptability interviews will be conducted in a private setting, and patients and caregivers will be interviewed independently to collect their true perspectives. Open-ended questions will query participants about their experiences with their assigned intervention components, the decision support coach, study procedures, and how the program impacted their decision-making. Additionally, interviews will solicit any changes they would like to see in the intervention and study procedures (Table 2 for the interview protocol for patients and caregivers). Table 2Interview guide for patients and caregiversType of questionPatientCaregiverOpeningTo begin, I would like to hear a little bit about you. Tell me who you are and what you do/did for a living?Same prompt as patientVery briefly and without going into detail, tell me about your chronic kidney disease and the treatment you are currently undergoingVery briefly and without going into detail, tell me about your caregiving experience supporting someone with chronic kidney disease and the treatment they are currently undergoingComponent perception— Now I’d like to hear what you thought of the programFor those who received content—How would you describe it to someone who had never heard of it?How would you describe it to someone who had never heard of it?For those who did not receive content – Did you caregiver share any aspects of the program with you? If yes, what did they share?For those who received content—What did you like most, what made you like those things? What was most helpful? What did you like least, and what made you dislike those things? What was least helpful?Same prompts as patientComponent impactFor those who did not receive content—Based on their behaviors around communication—have you noticed a change when you and your caregiver discuss your kidney disease, or have they encouraged you to discuss more things at your medical appointments?Based on their behaviors around communication—have you noticed a change when you all discuss their kidney disease or when they discuss their disease with their kidney doctor?For those who did not receive content -How useful was the session with your coach? Did any of the sessions change something about what you were thinking, feeling, or doing? Please describe. How do you think these sessions impact your ability to manage and make decisions about your chronic kidney disease?Same prompt as patientSession objectives impactFor those who received content share the learning objectives from the sessions—Describe how the program impacted these learning objectives and if they needed more time or less time on these objectives to be successfulSame prompt as patientCoaching—I’d like to hear what you thought about your decision support coach/For those who received content—What was your experience like with this person? What things were most helpful about your relationship with him/her? What things could we improve about how you worked with this person?Same prompt as patientPhysical education materials—I’d like to hear what you thought about the educational materialsFor those who received content—Were you able to see the educational materials? If yes, I’d like to hear what you think about the educational materialsSame prompt as patientFor those who did not receive content— Did your caregiver discuss any aspects of their program with you or share their toolkit?Alignment of surveysHas participation in the program impacted any questions, anxiety, or stress that you have experienced around your ability to make decisions about your treatment, either currently or in the future?Has participation in the program impacted any questions, anxiety, or stress that you have experienced around your loved ones’ illness and any potential decisions they may have to make related to their health?How do you think your participation in the program will impact or has already impacted your ability to make decisions about your family member’s or friend’s treatment or course illness?InvolvementFor those who received content—Are there parts of the program that you have spoken with your caregiver about?Are there parts of the program you have spoken to your loved one about?For patients who did not receive content— How do you feel when hearing what your caregiver received compared to your participation being limited to data collection?Overall recommendation for changeWhat changes you haven’t already mentioned should we make to the component moving forward?Same prompt as the patientClosing thoughtsAre there any other closing thoughts that you would like to share concerning your experiences with the ImPart program?Same prompt as the patient Interview guide for patients and caregivers Role of decision support coach, their training, and oversight The lay navigator performs as a decision support training coach. Lay navigators do not typically have formal healthcare backgrounds but are respected, trusted, and culturally savvy community members [46]. The core competencies for the decision support coaches include establishing a therapeutic, long-lasting partnership with participants, providing information and opportunities to enhance participant skills via an evidence-based connection, and facilitating problem-solving and action planning. Activities or needs outside these categories are referred to the study team to address. This includes disclosures of high distress through coaching calls or overall scores on data collection measures (Hospital Anxiety and Stress Scale). The protocol requires the coach or data collector to call the study PI, who has a protocol to contact the participant to perform an assessment, and based on the response and permission, will make connections back to their health care provider. Informed by the work of members of our team [45, 47], a 20-hour structured training program for coaches was implemented using the Canvas online platform. Training is designed to augment learning for those with no healthcare background and consists of independent readings, online interactive modules, videos, and a demonstration of coaching techniques through role-play. In addition, the study protocol, procedures, treatment manual, and manualized content scripts are reviewed. To date, two coaches have been trained. One coach is patient-participant-focused, and the second is caregiver-focused. Fidelity monitoring Intervention fidelity is ensured via multiple avenues based on the NIH TIdieR guidelines [47, 48]. First, as described above, all coaches receive standardized training. Second, coaches use condition-specific scripts for each unique condition. Third, all intervention contacts are recorded in charted templates, designed specifically for each of the eight conditions. Fourth, all ImPart sessions are audio recorded, and 20% are randomly selected each quarter for fidelity monitoring by a team member using a checklist based on the protocolized condition-specific script. For any coach whose ratings fall below 80%, the PI will initiate and guide re-training. Data collection, measures, and management The study’s conceptual framework (Fig. 1) led to the selection of all study measures (Table 3). Measures are collected at baseline, 12 weeks, and 24 weeks via a masked process. However, the FIM, IAM, and AIM as measures of intervention procedures and processes are only administered at 12 weeks to collect participants’ thoughts most immediately after intervention completion. At each time point, surveys are mailed to participants to complete and return; a prepaid, self-addressed envelope is included if they choose to return via the mail [45]. Survey responses collected via mail or phone collection are entered into the REDCap database. Participants may also choose to directly enter their responses into the REDCap via survey link or QR code. Participants are paid via a Greenphire ClinCard in escalating amounts for each time point: $30 for baseline, $35 for 12-week, $40 for 24-week measurement completion, and $40 for the acceptability interview. To maintain confidentiality, all participants will be assigned a unique code that will be written on paper questionnaires and assigned to transcripts and audio recordings of the acceptability interviews. The participant’s name and the code they are assigned will be stored in REDCap, which is protected behind the institution's firewall and accessible only to study team members. Table 3Aims, outcomes, and associated measuresOutcome: measureDescriptionReliabilityPrimary outcomeFeasibility (patient and caregiver): Study Process & Intervention and Feasibly of Intervention Measure (FIM)(Weiner et al., 2017) [49]Feasibility of protocol: Intervention completion rate (# participants completing assigned components) & assessment completion rate (# participants completing each study assessment [Baseline, 12, 24 weeks]) will be tabulated, ≥ 75% completion rates for assigned components & study assessments will be considered evidence of feasibilityFIM: The FIM is part of a four-item measure of implementation outcomes that are often considered “leading indicators” of implementation successAcceptability (patient and caregiver): Interviews & Acceptability of Intervention Measure (AIM) and Intervention Appropriateness Measure (IAM)(Weiner et al., 2017) [49]Acceptability Interviews: thematic analysis of digitally recorded, semi-structured qualitative interviews using a protocol adapted from prior study teams' work (Interview Guide in Supplement)AIM and the IAM: The AIM and IAM are two components of a four-item measure of implementation outcomes that are often considered "leading indicators" of successful implementationSecondary outcomesDecision Conflict (patient): Decision Conflict Scale(O'Connor, 1995, Goh, et al., 2022)) [50, 51]16 items that measure perceptions of uncertainty in choosing options, factors contributing to uncertainty (e.g., feeling uninformed, unclear values), and feeling that decisions were informed and values-basedRationale for use: Chosen for its ability to assess uncertainty in decision-making, particularly when individuals feel uninformed or unclear about their values, aligning well with the goals of our interventionTest-retest =.81; Cronbach’s alpha =.87Distress (patient and caregiver): Hospital Anxiety and Depression Scale (HADS) (Snaith, 2003; Wells et al., 2021) [52, 53]14 items; Two subscales: anxiety (e.g., feeling tense, restless, worry; 7 items) and depressive symptoms (e.g., cheerfulness, feeling slowed down; 7 items)Rationale for use: Selected for its efficiency in assessing anxiety and depression without confounding somatic symptoms, making it ideal for evaluating psychological distress in clinical populationsCronbach’s alpha: anxiety =.83; depressive symptoms =.82Health-Related Quality of Life (caregiver): Patient-Reported Measurement Information System (PROMIS) Global Health 10(Hays et al., 2009; Tay, et al., 2022) [54, 55]10 items that measure global HRQOL in 2 domains: physical and mental healthRationale for use: Captures physical and mental aspects of HRQOL and is well-suited for exploring potential impact on caregiver quality of lifeTest-retest = ICC ≥.85Kidney Disease Quality of Life (patient): Kidney Disease Quality of Life Scale (KDQOL 36) (Peipert et al., 2018) [56]36 items that measure three components: physical health score, mental health score, and kidney disease health score. Physical health score, mental health score., and kidney disease health score are averaged scores of sub-scalesRationale for use: Widely utilized scale providing a comprehensive view of physical, mental, and kidney disease-specific health, offering averaged scores that support targeted assessment of overall well-beingCronbach's alpha total scale: greater than 0.700 all domainsSocial support (patient): Rini’s Social Support Effectiveness Scale[34, 57]25 items that measure the amount, quality, and skillfulness of support from friends and relatives, including task, emotional, and informational support subscalesRationale for use: While not widely used in CKD decision-making literature before, this scale captures key types of social support—task, emotional, and informational—that influence decision-making in CKDCronbach’s alpha =.95Dyadic Interaction (patient and caregiver): Dyadic Coping Inventory (Tkachenko, et al., 2019; ) [58]37 items: designed to measure perceived communication and dyadic coping in close relationships when one or both partners are stressedRationale for use: Selected to assess how partners communicate and cope together during stress, offering insight into relational dynamics that may influence decision-making and emotional well-beingCronbach’s aloha =.09 Aims, outcomes, and associated measures Feasibility (patient and caregiver): Study Process & Intervention and Feasibly of Intervention Measure (FIM) (Weiner et al., 2017) [49] Feasibility of protocol: Intervention completion rate (# participants completing assigned components) & assessment completion rate (# participants completing each study assessment [Baseline, 12, 24 weeks]) will be tabulated, ≥ 75% completion rates for assigned components & study assessments will be considered evidence of feasibility FIM: The FIM is part of a four-item measure of implementation outcomes that are often considered “leading indicators” of implementation success Acceptability (patient and caregiver): Interviews & Acceptability of Intervention Measure (AIM) and Intervention Appropriateness Measure (IAM) (Weiner et al., 2017) [49] Acceptability Interviews: thematic analysis of digitally recorded, semi-structured qualitative interviews using a protocol adapted from prior study teams' work (Interview Guide in Supplement) AIM and the IAM: The AIM and IAM are two components of a four-item measure of implementation outcomes that are often considered "leading indicators" of successful implementation Decision Conflict (patient): Decision Conflict Scale (O'Connor, 1995, Goh, et al., 2022)) [50, 51] 16 items that measure perceptions of uncertainty in choosing options, factors contributing to uncertainty (e.g., feeling uninformed, unclear values), and feeling that decisions were informed and values-based Rationale for use: Chosen for its ability to assess uncertainty in decision-making, particularly when individuals feel uninformed or unclear about their values, aligning well with the goals of our intervention 14 items; Two subscales: anxiety (e.g., feeling tense, restless, worry; 7 items) and depressive symptoms (e.g., cheerfulness, feeling slowed down; 7 items) Rationale for use: Selected for its efficiency in assessing anxiety and depression without confounding somatic symptoms, making it ideal for evaluating psychological distress in clinical populations Health-Related Quality of Life (caregiver): Patient-Reported Measurement Information System (PROMIS) Global Health 10 (Hays et al., 2009; Tay, et al., 2022) [54, 55] 10 items that measure global HRQOL in 2 domains: physical and mental health Rationale for use: Captures physical and mental aspects of HRQOL and is well-suited for exploring potential impact on caregiver quality of life 36 items that measure three components: physical health score, mental health score, and kidney disease health score. Physical health score, mental health score., and kidney disease health score are averaged scores of sub-scales Rationale for use: Widely utilized scale providing a comprehensive view of physical, mental, and kidney disease-specific health, offering averaged scores that support targeted assessment of overall well-being Social support (patient): Rini’s Social Support Effectiveness Scale [34, 57] 25 items that measure the amount, quality, and skillfulness of support from friends and relatives, including task, emotional, and informational support subscales Rationale for use: While not widely used in CKD decision-making literature before, this scale captures key types of social support—task, emotional, and informational—that influence decision-making in CKD 37 items: designed to measure perceived communication and dyadic coping in close relationships when one or both partners are stressed Rationale for use: Selected to assess how partners communicate and cope together during stress, offering insight into relational dynamics that may influence decision-making and emotional well-being Sample size considerations The target sample consists of 64 patient-caregiver dyads (128 total participants) who will be recruited over 36 months [59]. The sample size is not powered for formal statistical inference, but the sample of 64 dyads is consistent with recommendations for pilot studies [60, 61] of sample sizes ≤ 70. The size is pragmatic for recruiting dyads to demonstrate initial rates of recruitment from one academic medical center and is consistent with pilot studies using a lay-navigator approach, whose goal was also to examine feasibility and acceptability [24, 62–64]. From the perspective of precision of an estimate for a future study, assuming a completion proportion of 0.75 for enrolled dyads, with n = 64, a 68% Confidence Interval (approximately ± 1 standard error from the point estimate) for this proportion is 0.69 to 0.81, and a 95% Confidence Interval (approximately ± 2 standard errors from the point estimate) is 0.64 to 0.86. The precision provided by the sample size was considered adequate given the goals of the study. From the perspective of detecting implementation issues, with N = 64, assuming the true probability that an issue is experienced ranging from 0.05 to 0.1 by a participating dyad, the probability that the issue occurs at least once in the sample ranges from 0.96 to 0.99, which ensures obtaining information necessary for refinement of procedures for a future study (computations conducted in PASS 24 software [65]). Data analysis Given the exploratory rather than confirmatory nature of a pilot study, the objective of the data analyses is exploratory, rather than formal hypothesis testing. Feasibility will be assessed by objectively calculating the intervention completion rate of each participant to determine if greater than 75% complete assigned components and study surveys at baseline, 12, and 24 weeks. Completion is considered when a participant has participated in all coaching components of the assigned condition (see Table 1) and they have returned study surveys within the specific data collection timeframe. We can assess intervention completion through coach documentation. Additionally, since the team tracks screening and recruitment rates, we will utilize this information to enhance our understanding of recruitment statistics and identify any necessary modifications. While we do not have a set percentage for a successful recruitment rate, we are currently monitoring our recruitment rate and have plans to expand recruitment avenues (i.e., in-person clinic recruitment and adding additional clinicians whose clinics will be screened for potential participants). This will provide us with real-time data to adjust recruitment strategies over the 3-year study period, enabling us to identify the most successful method or combination of methods for use in the fully powered optimization trial. When combined, these feasibility data points will help us understand if conducting this trial with these procedures (screening, recruitment, intervention delivery, data collection) is feasible in our next trial and are aligned with pilot studies our team has conducted, as well as nephrology decision-making focused pilots [24, 63, 66]. Means will be calculated for the FIM, AIM, and IAM. Given their inherent subjectivity and dependence on context, these measures are being evaluated in tandem with qualitative feedback. To accomplish this, acceptability will also be assessed, qualitatively, via thematic analysis of the interview data. Inductive and deductive thematic analysis will involve trained members of the study team (at least 2) reading the transcribed interviews independently and creating an initial set of codes associated with the theoretical model and codes that emerge in vivo. After the first 2 transcripts have been coded, the coders will meet to discuss their findings and resolve any conflicts. When a final list of codes is created, that code list will be used for the remaining transcripts. As disputes arise, the coding team will meet to discuss and resolve them. Feasibility and acceptability data will inform and support any decisions made by the study team in collaboration with the community advisory board to update/refine poor-performing trial procedures (i.e., recruitment, component leveling/content, data collection procedures) as we seek to progress from a pilot to a fully powered optimization trial [64, 67]. We will also track screening, eligibility, enrollment rates, reasons for non-consent of eligible individuals, and reasons for participant dropout. An intent-to-treat main analysis will use all available data from baseline through Week 24. Following factorial trial modeling approaches [28], we will use linear mixed-effect modeling to address this aim. The main effect of a component is estimated based on comparing the component level across experimental conditions (Table 1): the main effect of caregiver social support effectiveness psychoeducation will compare the mean of conditions 1–4 (1 session) vs. conditions 5–8 (3 sessions); the main effect of caregiver decision support communication training will compare the mean of conditions 1, 2, 5, and 6 (1 session) vs. conditions 3, 4, 7, and 8 (no sessions); and the main effect of the patient psychoeducation training will compare the mean of conditions 1,3,5, and 7 (2 sessions) vs. the mean of conditions 2, 4, 6, and 8 (no sessions). The same approach will be taken to explore potential moderating effects of race, capitalizing on randomization stratification. Oversight and monitoring Data monitoring committee A safety monitoring committee (SMC) oversees this trial, led by two researchers external to the team with expertise in statistics and clinical trials. The SMC relies on established procedures when reviewing protocols and procedures and when deciding the method and frequency of study review. As a low-risk trial, the principal monitors are the PI (SG) and her primary mentor (JNO). Annually, a data summary and safety information are submitted for review. The PI and primary mentor perform tasks related to participant safety, which include (1) assessing for potential risks associated with recruitment and participation and (2) designing and implementing procedures that minimize participant risks that have been defined in advance and that could be related to intervention and/or study procedures. It is unlikely that serious adverse events related to the study intervention or procedures will occur, as this is a minimal-risk trial. The PI has developed plans to detail any protocol changes to the IRB, funders, and clintrials.gov. Annually, updates to clintrials.gov will occur when the study’s annual progress report is submitted to funders which happens in the early part of the year—January–February. Dissemination plans Summary results will be reported to the funder no later than one year after completion, and the trial is registered in Clinicaltrials.gov as NCT06173323. In addition, results will be shared via publication and conference proceedings that will be informed by members of the CAB who have membership and/or association with professional organizations (American Society of Nephrology Kidney Week) and more patient-focused organizations (National Kidney Foundation and American Association of Kidney Patients). This study’s dataset will not be published in an open-access format, but requests for the study’s final dataset can be made to the PI. Discussion Our pilot research and others have found that individuals with CKD and their caregivers typically work in close partnership to make health-related decisions as kidney disease progresses [6, 68–70]. Optimizing this partnership is thought to lead to more preference-aligned decisions, less distress, higher care satisfaction, and better patient outcomes. While interventions have been developed and tested to increase knowledge [71, 72] and to enhance involvement in advanced care planning in older patients [73, 74], few have focused on developing the decision support skills of the patient living with stage 4 disease and their caregiver specifically targeting the multiple healthcare decisions that must be made before end-stage disease occurs. To address this gap, our team has developed ImPart. This dyadic decision-support intervention is undergoing pilot testing using a factorial trial approach in combination with a community-engaged framework to explore the feasibility, acceptability, and preliminary efficacy of intervention components. This pilot study will inform the design of a future fully powered factorial trial through its use of quantitative and qualitative data generated and relevant external data from similar interventions. The complexity of the design gives us the participant-level data that we need to assess feasibility, acceptability, and preliminary effectiveness, as each condition will have an adequate number of participants to provide the team with insights into how to improve the intervention, study process, and procedures for a future trial. While limited in being able to fully support power calculations independently, it will provide valuable preliminary estimates and feasibility insights. We are also exploring comparable studies to supplement these calculations and strengthen the rationale for sample size decisions [29, 45]. Additionally, we plan to align the secondary outcomes of the pilot with those of the future trial, with the intent to assess whether specific components of the intervention show promise in impacting key secondary outcomes, thereby guiding the scope and focus of the subsequent study. Thus, we emphasize that our future R01 optimization factorial trial objectives will differ in that for the R01 we aim to (1) identify which component and at which levels contribute meaningfully to an identified primary outcome; this outcome will be identified based on the preliminary effectiveness data; and (2) the results of the R01 will be applied to build a version of ImPart composed of only practical components. While this protocol has stated strengths, there is a limitation in our inability to enroll those who cannot speak or understand English. While we acknowledge and are making plans to include individuals who are non-English speaking (specifically exploring Spanish-speaking opportunities) in our subsequent protocols, our current site for recruitment for this pilot study has a lower number of individuals who identify within this specific demographic. We have limited ability to deliver a robust coaching intervention to those who do not speak English, as we have no translation services, nor the ability to transcribe our materials into additional languages. Conclusion Effective decisional partnership and understanding the value of social support are vital skills for those with CKD and their caregivers to reduce distress and decisional conflict when making health-related decisions. ImPart is a coach-led decision support intervention that aims to empower dyads with the skills needed to make high-quality, value-based health-related decisions before illness becomes severe. The goal is to have dyads (1) contemplate the decision needed; (2) positively deal with emotions; (3) request resources/support; and (4) make an informed patient-centered decision. The results of this pilot factorial trial, including the pilot feasibility and acceptability data, will inform a fully powered R01 factorial study to test the effects of individual ImPart components on CKD patient and caregiver outcomes. Pilot data will drive protocol refinement decisions, including how to include additional sites to enhance and expand recruitment strategically. Ultimately, they will guide the refinement of components, component context, and component leveling based on the MOST framework. Acknowledgements The authors want to thank the ImPart coaches, Alica Cole and Narsharra Oden-Hampton, and partnering nephrologists who assisted with the identification of patient and family caregivers, recruitment, retention, data collection, and payment. The authors would also like to thank all the patients and caregivers participating in this study (both now and in the future), including Mr. Pazant, who lends an additional patient voice to our community advisory board meetings. Disclosure The content is solely the responsibility of the authors and does not represent the official views of the NIH or federal government. Authors’ contributions Shena Gazaway: writing—investigation, methodology, original draft preparation, reviewing, and editing; conceptualization, project administration. Claretha Lyas, Katina Lang-Lindsey, Richard Knight, Patricia Pazant, Neil Gustafson, Ann Rayburn, Ebele Umeukeje: writing—reviewing and editing; conceptualization, methodology. Rachel Wells, AlicaCole, Tamara Nix-Parker; Leslie Pitts: project administration, investigation, writing—reviewing and editing. Orlando M. Gutierrez, Andres Azuero, and J. Nicholas Odom: supervision—conceptualization, methodology; writing—reviewing and editing. Funding The National Institutes of Health/National Institutes of Diabetes, Digestive, Kidney, and Urology Disorders (K23DK134756—PI: Gazaway) supports this trial. Dr. Rachel Wells is funded by the National Institute of Nursing Research (R00NR019854—PI: Wells). Data availability No data was used in the research described. The Interview Guides (patient and caregiver) are shared within the article as Table 2. Declarations Ethics approval and consent to participate The trial study is approved by the University of Alabama at Birmingham Institutional Review Board (IRB-300012221) and is being conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. Informed consent is being obtained from all participants. The trial is registered as NCT 06173323. Consent for publication A copy of the IRB-approved information sheet/consent form has been provided as a supplemental file. Competing interests The authors have no competing interestes to disclose. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No data was used in the research described. The Interview Guides (patient and caregiver) are shared within the article as Table 2.